U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align U.S. costs with those in other wealthy nations. Bristol Myers Squibb (BMY.N), opens new tab, Gilead Sciences (GILD.O), opens new tab, Merck (MRK.N), opens new tab and Roche's (ROG.S), opens new tab U.S. unit Genentech have struck deals. Novartis (NOVN.S), opens new tab, Amgen (AMGN.O), opens new tab, Boehringer Ingelheim, Sanofi (SASY.PA), opens new tab and GSK (GSK.L), opens new tab have also signed on.